Owing to the high prevalence of the CYP2D6*17 variant among the black Zimbabwean population, the results of this study might provide benefit for breast cancer patients upon the introduction of personalised TAM therapy in Zimbabwe. The gene discussed is CYP2D6; the disease is breast cancer.